



NON-EXECUTIVE DIRECTOR RETIREMENT AND RECRUITMENT

02 April 2026, Adelaide, Australia: Mayne Pharma Group Limited (Mayne Pharma or the Company) (ASX: MYX), today announces that Dr Kathryn (Katie) MacFarlane, PharmD, will retire from the Board at the end of May 2026.

Dr MacFarlane's decision to retire is due to her recent appointment as Chief Executive Officer of a US-based biopharma company, which will commence in May 2026. Dr MacFarlane has served as a Director of Mayne Pharma since February 2022 and is currently Chair of the Science, Technology and Medical Committee.

Professor Bruce Robinson said *"On behalf of the Board, I want to thank Katie for her contribution and service to Mayne Pharma during her tenure. We wish Katie all the best in her new role."*

Mayne Pharma has commenced a process to recruit an additional Non-Executive Director with appropriate skills and experience to join its Board. The Board has appointed an independent executive recruitment firm to manage the process.

- ENDS -

For further information contact:

Dr Tom Duthy
Investor Relations
+61 402 493 727
ir@maynepharma.com

Authorised for release to the ASX by the Board of Directors.

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women's health in the United States and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.